Opko Curna, LLC
Records under this name other than the patents Opko Curna, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,153,606 | Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,329 | Treatment of Erythropoietin (EPO) Related Diseases by Inhibition of Natural Antisense Transcript to Epo Formerly held In force · High confidence | In force | High confidence | |
| US 9,012,139 | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,895,527 | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,074,210 | Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,927,511 | Treatment of Vascular Endothelial Growth Factor (VEGF) Related Diseases by Inhibition of Natural Antisense Transcript to VEGF Formerly held In force · High confidence | In force | High confidence | |
| US 9,155,754 | Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,023,822 | Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,859,515 | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,330 | Treatment of Down Syndrome Gene Related Diseases by Inhibition of Natural Antisense Transcript to a Down Syndrome Gene Formerly held In force · High confidence | In force | High confidence |